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Abstract
Galectin-8 (Gal-8) is a member of a glycan-binding protein family that regulates the immune
system, among other functions, and is a target of antibodies in autoimmune disorders. How-
ever, its role in multiple sclerosis (MS), an autoimmune inflammatory disease of the central
nervous system (CNS), remains unknown. We study the consequences of Gal-8 silencing
on lymphocyte subpopulations and the development of experimental autoimmune encepha-
litis (EAE), to then assess the presence and clinical meaning of anti-Gal-8 antibodies in MS
patients. Lgals8/Lac-Z knock-in mice lacking Gal-8 expression have higher polarization
toward Th17 cells accompanied with decreased CCR6+ and higher CXCR3+ regulatory T
cells (Tregs) frequency. These conditions result in exacerbated MOG35-55 peptide-induced
EAE. Gal-8 eliminates activated Th17 but not Th1 cells by apoptosis and ameliorates EAE
in C57BL/6 wild-type mice. β-gal histochemistry reflecting the activity of the Gal-8 promoter
revealed Gal-8 expression in a wide range of CNS regions, including high expression in the
choroid-plexus. Accordingly, we detected Gal-8 in human cerebrospinal fluid, suggesting a
role in the CNS immune-surveillance circuit. In addition, we show that MS patients generate
function-blocking anti-Gal-8 antibodies with pathogenic potential. Such antibodies block cell
adhesion and Gal-8-induced Th17 apoptosis. Furthermore, circulating anti-Gal-8 antibodies
associate with relapsing-remitting MS (RRMS), and not with progressive MS phenotypes,
predicting clinical disability at diagnosis within the first year of follow-up. Our results reveal
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that Gal-8 has an immunosuppressive protective role against autoimmune CNS inflamma-
tion, modulating the balance of Th17 and Th1 polarization and their respective Tregs. Such
a role can be counteracted during RRMS by anti-Gal-8 antibodies, worsening disease prog-
nosis. Even though anti-Gal-8 antibodies are not specific for MS, our results suggest that
they could be a potential early severity biomarker in RRMS.
Introduction
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system
(CNS) that damages myelin and axons in the brain and spinal cord [1, 2]. Most (80%) of
patients are diagnosed with the relapsing-remitting form of MS (RRMS) and 60% of them
evolve towards secondary progressive MS (SPMS) [1]. A subset of patients (20%) exhibits pri-
mary progressive MS (PPMS) displaying worse evolution than RRMS patients from the begin-
ning [1]. Such wide variations in the phenotype and aggressiveness of the disease are also
reflected in the characteristic heterogeneity in presentation, evolution and treatment responses
of RRMS [1, 3, 4]. Although the pathogenic mechanisms remain little understood, during
RRMS an autoimmune-driven inflammation of variable intensity and dynamics predominates,
underlying the severity of clinical evolution [1]. Observations in RRMS patients, as well as in
the MS preclinical mouse model of experimental autoimmune encephalomyelitis (EAE), sug-
gest that disease pathogenesis and resolution depends on a fine balance between the autoim-
mune inflammation mediated by effector Th1 and Th17 lymphocytes [3, 5] and the immune
tolerance promoted by suppressive regulatory T cells (Tregs) [6, 7]. Subpopulations of Tregs
expressing either CXCR3 or CCR6 chemokine receptors, respectively, suppress Th1 or Th17-
mediated inflammation [8–11], and are recruited to the CNS during neuroinflammatory pro-
cesses [12, 13], but their role in MS and EAE remains unclear [6]. An additional enigmatic
aspect regards the pathogenic role of antibodies, which remains contentious and has mainly
been explored focusing on neuronal and myelin elements as antigenic targets [3, 14]. There-
fore, modulators of Th1, Th17 and Treg cell homeostasis and their eventual neutralization
by function-blocking antibodies entail great interest. Their study might not only reveal new
determinants of worse disease evolution but also suggest new prognostic and/or therapeutic
approaches.
Galectins are a family of glycan-binding proteins that has emerged as strong modulators of
adaptive and innate immunity [15]. These lectins are secreted by an unconventional mecha-
nism and have the potential to modify the function of a variety of cell surface glycoproteins,
including signaling receptors and integrins involved in immune-related cellular processes [16–
18]. The conserved carbohydrate-recognition domains (CRDs) of galectins recognize β-galac-
tosides, displaying variations that result in unique fine specificities for more complex galac-
tose-containing oligosaccharides and specific downstream effects [19–22]. In this way,
different galectins can play redundant or complementary roles in autoimmune diseases by
modulating the homeostasis of B and T cells [15], including Th1, Th17 cells and Tregs [15].
Among the 15 members of the galectin (Gal) family, only Gal-1, Gal-3, and Gal-9 have been
systematically studied in EAE [20, 23–26].
Gal-8 is a tandem-repeat galectin that, unlike other galectins, possesses unique high affinity
for α-2,3-sialylated glycans in its N-terminal carbohydrate recognition domain (CRD), which
is linked by a short peptide to a C-terminal CRD bearing another glycan specificity [27, 28].
Gal-8 has been proposed to play immunosuppressive roles inducing apoptosis of activated T
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cells [29], including Th17 cells [30], and promoting differentiation of immunosupressive
Tregs [30, 31]. Treatment with Gal-8 ameliorates Th1 and Th17-mediated ocular pathology in
experimental autoimmune uveitis (EAU) [30]. Altered Gal-8 functions have been found in
rheumatic, autoimmune and inflammatory human disorders [32, 33]. A single aminoacid
polymorphism (F19Y) with functional implications on cancer cell growth [34] and glycan
interactions [35], strongly associates with rheumatoid arthritis [36]. Interestingly, neutralizing
anti-Gal-8 autoantibodies that block Gal-8 interactions with glycans on β1-integrins and LFA-
1 [37, 38], as well as Gal-8-induced apoptosis of T cells [29], are frequently generated in sys-
temic lupus erythematosus (SLE), the prototypic autoimmune disease, and also in rheumatoid
arthritis and probably other inflammatory disorders [39]. However, the role of Gal-8 and its
neutralizing antibodies have not yet been explored in MS.
Here we study: 1) How the absence of Gal-8 function in a Gal-8 KO mice impinges upon
lymphocyte subpopulations and EAE severity; 2) The effect of Gal-8 treatment on EAE of wild
type mice; 3) The presence and clinical meaning of autoantibodies against Gal-8 in patients
with MS. Our results indicate a protective immunosuppressive role of Gal-8 against CNS auto-
immunity involving apoptotic elimination of activated Th17 cells and opposite dysbalances of
CXCR3+ and CCR6+ Treg frequencies. Strikingly, MS patients generate neutralizing anti-Gal-
8 antibodies that can block the Gal-8 immunosuppressive function and impact upon RRMS
prognostic. Patients recently diagnosed with RRMS and harboring anti-Gal-8 antibodies in
serum, before establishing the treatment, develop a more aggressive disease within just one
year of evolution, as shown by monitoring the Expanded Disability Status Scale (EDSS). Over-
all, the evidence suggests that Gal-8 plays an immunosuppressive function that can be counter-
acted by anti-Gal-8 antibodies in RRMS leading to worse evolution. Although Gal-8 function-
blocking antibodies are not specific to MS, as they can be found in other autoimmune diseases
[39], their presence in context of RRMS might be useful as an early biomarker of worse
evolution.
Material and methods
Study approval
The Scientific Ethics Committee CEC-MED-UC and the Science Ethics Committee for Animal
and Environmental Care of the Pontificia Universidad Cato´lica de Chile (PUC) approved the
informed consent voluntarily given by MS patients and all animal procedures, respectively.
Patients and clinical variables
MS patients were monitored by trained neurologists in the Center of Multiple Sclerosis PUC,
between 2011 and 2013, during standard clinical visits, by collecting demographic data, rele-
vant clinical history, neurologic assessments, including the Expanded Disability Status Scale
(EDSS), relapse symptoms and Magnetic Resonance Imaging (MRI) using 1.5 Tesla MRI with
5 mm thick slices and 2.5 mm separation between each slice. Clinically relevant EDSS worsen-
ing implied changes from 0 to 1.5 or increments of 1 point within the range of 1 to 5.5 scores.
Blood samples were obtained from RRMS patients before starting treatment with any disease-
modifying drugs (DMD). Patients with progressive forms were not receiving any DMD or
immunosuppressant drugs at least 6 months before the blood samples. No steroid treatment
was used in RR, SP or PP patients for at least 4 weeks prior to the blood sample. Patients were
followed up for an average of one year, controlled every 3 to 6 months, or more frequently (e.g.
during relapses), as needed. All patients accepted and signed the informed consent approved
by the Scientific Ethics Committee CEC-MED-UC.
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Antibodies and reagents
To determine expression levels of key surface and intracellular molecules associated with dif-
ferent T-cell phenotypes, splenocytes were immunostained with different combinations of the
following fluorochrome-conjugated monoclonal antibodies (mAbs) at room temperature for
30 min: allophycocyanin (Apc)-conjugated anti-FoxP3 (clone FJK-16S) and R-Phycoerythrin
(PE)-conjugated anti-RORγt (clone BSD), both from eBioscience (San Diego, CA). Otherwise,
PerCP/Cyanine dye 5.5 (PerCP/Cy5.5)-conjugated anti-CCR6 (clone 29-2L17), PE/Cyanine
dye 7 (PE/Cy7)-conjugated anti-CD4 (clone GK1.5), Brilliant-Violet 421TM (Bv421)-conju-
gated anti-CXCR3 (Clone CXCR3-173), PE-conjugated anti-CD44 (clone IM7), APC-conju-
gated anti-CD25 (clone PC61) and APC/Cyanine dye 7 (APC/Cy7)-conjugated anti-CD62L
(clone MEL14) were purchased from Biolegend (San Diego, CA). PerCP-conjugated anti-CD4
(clone RM4-5), PECy7-conjugated IFN-γ (clone XMG1.2) were purchased from eBioscience.
Alexa 647-conjugated IL-17A (clone TC11-18H10.1), PE-conjugated anti-IFN-γ and Alexa
488–conjugated anti-IL-17 were purchased from BioLegend. Alexa 488-conjugated anti-CD8a
(clone 53–6.7), alexa 647-conjugated anti-CD19 (clone 1D3), PE-conjugated anti-CD11c
(clone HL3), PE-conjugated anti-IL4 (11B11), Alexa 647-conjugated anti-IL17A (clone TC11-
18H10), PE/Cy7-conjugated anti-IFN-γ (cloneXMG1.2) were purchased from BD Biosci-
ences-Pharmingen. For T cell activation, anti-mouse CD28 (clone 37.51) and anti-mouse CD3
(clone 145-2C11) were purchased from BD Bioscience.
Ionomicina, brefeldin A and PMA (Phorbol Myristate Acetate) were purchased from
Sigma-Aldrich. GST-Gal-8 expressed in bacteria was isolated by affinity chromatography and
Gal-8 was released by thrombin treatment as described [37].
Animals
Mice were mantained under conditions of strict confinement, which included automatic con-
trol of temperature (21˚C) and photoperiod (12 h light / 12 h dark). Lgals8/Lac-Z knock-in
(here called Gal-8 KO or Lgals8-/-) mice were generated from C57BL/6NTac mice engineered
in Regeneron Pharmaceuticals Inc., New York, using Velocigene technology for replacing the
entire coding region of the mouse Lgals8 gene (18,427 bp) with LacZ lox-Ub1-EM7-Neo-lox
Cassette containing the LacZ gene that encodes β-galactosidase [40]. Details of the Lgals8 KO
mice and PCR genotyping assay, including the predicted PCR products and the primers, are
available at the Velocigene website (www.velocigene.com/komp/detail/14305). IL-17A-GFP
reporter mice in the C57BL/6J background, which express EGFP under the control of the IL-
17A promoter, were purchased from Jackson Laboratories (Bar Harbor, ME).
EAE induction, scoring and treatment
EAE was induced in 8-12-week-old Lgals8-/- and Lgals8+/+ mice by immunization of an emul-
sion containing 150 μg of MOG35-55 peptide (MOGp) (Biosynth International) and 500 μg of
Mycobacterium tuberculosis extract (Difco Lab.) in incomplete Freund’s adjuvant oil. In addi-
tion, mice received 200 ng of pertussis toxin (List Biological Laboratories) on day 0 and 2 post-
immunization (p.i.). Clinical progression of EAE symptoms were monitored daily using the
following scale: 0, no clinical signs; 1, loss of tail tone; 2, flaccid tail; 3, incomplete paralysis of
one or two hind legs; 4, complete hind limb paralysis; 5, moribund (animals that do not move,
do not consume water or food, that loss weight greater than 20% or have respiratory problems,
were euthanized); 6, death. In some experiments, EAE was induced in wild-type C57BL/6J
mice and simultaneously treated (i.p.) with either 100 μg recombinant Gal-8 or PBS (control
group) during 20 consecutive days. Topical diclofenac (gel 1%) was used to alleviate animal
suffering. The use of local analgesia rather than systemic analgesia was favored to avoid
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unwanted influences on immunological and inflammatory parameters under study. The ani-
mals were euthanized by cervical dislocation after CO2 sedation.
CNS ß-gal histochemistry and histological analysis
Brains were fixed by perfusion in 4% paraformaldehyde (PFA) in PB buffer (0.1 M phosphate
buffer pH 7.4) and processed for β-gal histochemistry as described [41, 42]. Cross-sections of
spinal cords were obtained from mice at 20 days after EAE induction and immersion-fixed in
neutral buffered formalin solution. Inflammatory infiltrates and demyelination were histo-
chemically analyzed by hematoxylin and eosin (H&E) and luxol fast blue staining, respectively.
Subpopulation analysis of splenocytes
Splenocytes were isolated as described [43, 44] from 8-12-week-old female mice and analyzed by
FACS. For polyclonal T cell activation, splenocytes were grown in the presence of 1 μg/ml of
anti-CD3 with or without anti-CD28 antibodies for 72 h. For Gal-8 effects on antigen-specific T
cell activation, splenocytes were isolated after 10 days of EAE induction and re-stimulated with
10 μg/ml MOGp in the presence or absence of 100 μg/ml recombinant Gal-8 for 72 h. CD4+ T
cell subpopulations were analyzed in stimulated cells by incubating with 50 ng/ml PMA, 500 ng/
ml ionomycin, and 10 μg/ml brefeldin A for the last 4 h of culture. Cells were stained with Zom-
bie Aqua Fixable Viability kit (Biolegend) in PBS followed by staining for cell-surface markers
using flurophore-conjugated monoclonal antibodies against mouse CD4, CD19, CD8, CD11c,
CD25, CD44, CD62L, CXCR3 and CCR6. For intracellular staining, cells were washed, fixed,
and permeabilized with Cytofix/Cytoperm kit (BD Biosciences-Pharmingen) and incubated
simultaneously with fluorophore-conjugated antibodies against IFN-γ, IL-4, IL-17, Foxp3 and
RORγt. Samples were acquired with BD FACSVerse or FACSCantoTM II (BD) flow cytometers
and data was analyzed with FlowJo V10 software or CellQuest Pro software (BD Biosciences).
Th17 cell death analysis
To analyze apoptosis of Th17 cells differentiated in vitro, naive (CD62L+ CD44-) CD4+ T-cells
from IL-17A-GFP reporter or from wild-type mice were purified by cell sorting, resuspended
at 0.5x106 cells/ml in IMDM medium supplemented with antibiotics/antimycotics (Gibco)
and Gentamycin (Gibco), and incubated (200 μl/well) in 96-well plates preactivated with anti-
CD3 (50 μl/well at 2 μg/ml) at 37˚C, 90% humidity and 5% CO2. Cells were incubated for 3
days with mouse IL-6 (mI-6; 25 ng/mL), mIL-1ß (20 ng/ml), human TGF-β1 (hTGF-β1; 5 ng/
ml), anti-CD28 (2 μg/ml) and blocking antibodies anti-IFNγ, anti-IL-4 and anti-IL-2 (5 μg/ml
each). Afterwards, cells were washed, resuspended in fresh medium and incubated for addi-
tional 4 days in 96-well plates with mIL-6 (25 ng/ml) and hTGF-β1 (5 ng/ml). All cytokines
(Biolegend) used were carrier free. Differentiated Th17 cells were purified by cell sorting based
on IL-17A expression (GFP+), resuspended in supplemented IMDM and incubated (1x105
cells/well) in 96-well plates pre-activated with anti-CD3 and anti-CD28 (50 μl/well at 2 μg/ml
each) in the presence or absence of Gal-8 (20 μg/ml) for 72 h. The extent of apoptosis/necrosis
was determined with a commercial kit (Pacific Blue TM Annexin V Apoptopsis Detection Kit
with 7-AAD; 640926, Biolegend) analyzing death cells by FACS, in the CD4+ GFP+ gated pop-
ulation corresponding to70% of total cells, as observed in FSC versus SSC analysis. Gal-
8-induced cell death of Th17 lymphocytes was analyzed with a similar protocol, except that
naive CD4+ T-cells were isolated from WT C57BL/6 mice, differentiated Th17 cells were puri-
fied by using a commercial kit (from Biolegend) based on the surface expression of IL-17. Cell
death (Annexin V versus 7-AAD) was analyzed in the CD4+ gated population, which corre-
sponded to90% of total cells, accordingly to FSC versus SSC analysis.
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Detection of anti-Gal-8 autoantibodies
Western blot analysis was performed using recombinant Gal-8 to screen sera of patients with
MS for anti-Gal-8 antibodies, as previously described in patients with SLE or AR [39]. The
same positive and negative controls were included in each western blot and densitometric
analysis of the bands was performed by ImageJ. Bands that duplicate the intensity of the nega-
tive control in at least two independent experiments performed in triplicate and blinded with
respect to the sample were considered positive for anti-Gal-8 reactivity.
Detection of Gal-8 in human cerebro spinal fluid (CSF)
CSF collected for diagnostic purposes from individuals studied for diplopia, vertiginous syn-
drome (C7), cephalea, febrile syndrome and meningitis was analyzed for the presence of Gal-8
by immunoblot, using a rabbit anti-Gal-8 polyclonal antibody produced in our laboratory
[45]. CSF (1 ml) was centrifuged for 10 min at 1,000 g to eliminate debris and the supernatant
was incubated with 50 μl of α-lactose-agarose beads for 3 h at 4˚C in presence of anti-proteases
(2 μg/ml leupeptin, 2 μg/ml pepstatin and 2 mM PMSF). Lectins bound to α-lactose-agarose
beads were pulled down at 1,000 rpm for 3 min, the beads were washed three times with PBS
and suspended in 40 μl of electrophoresis loading buffer. The samples were heated for 5 min at
100˚C and loaded in 10% SDS-PAGE, transferred to nitrocellulose membranes and analyzed
with anti-Gal-8 antibodies.
Isolation of human peripheral blood mononuclear cells (PBMC)
Ten milliliters of peripheral blood was diluted with 10 ml of PBS, layered carefully over 7.5 ml
of Histopaque-1077 (Sigma Chem. Co.) and centrifuged at 400 x g for 30 min at room temper-
ature. Cells in the opaque interface were collected, diluted twice with 50 ml of PBS, centrifuged
at 250 x g for 10 min and resuspended in RPMI 1640 medium containing 10% FBS.
Cell adhesion assay
Cover slips were coated overnight at 4˚C with 10 μg/ml of Gal-8 in the absence or presence of
anti-Gal-8 autoantibodies, as described [37, 38, 46]. Serum-starved PBMCs isolated from
healthy people (200,000 cells/well) were plated on cover slips for 30 min at 37˚C. Adherent
cells were stained with Hoechst and quantified analyzing at least three random fields on three
cover slips.
Statistical analysis
The presence of anti-Gal-8 autoantibodies in RRMS, PPMS and SPMS patients was analyzed
respect to various clinical, radiological and CSF variables using Mann-Whitney U test (with
Tukey multiple comparisons) and SPSS Statistics 19.0 software. Yates chi-square corrected test
and Odds ratio were calculated with VassarStats. EAE disease scores were analyzed with
Mann–Whitney U test or one-way ANOVA Kruskal Wallis with Dunn post-test using Prism 5
software (GraphPad Software). Other analyses were made with two tailed non-paired Student’s
t-test as indicated in figure legends.
Results
Endogenous Gal-8 protects against EAE
To assess the role of Gal-8 in autoimmune CNS pathogenesis we first study how Lgals8 disrup-
tion affects EAE severity. We evaluated the development, progression and CNS inflammation
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in Lgals8-/- and Lgals8+/+ littermates immunized with MOG35-55 peptide (MOGp). The two
mouse groups had similar EAE incidence (85.2% Lgals8+/+ littermates and 86.2% Lgals8-/-).
However, Lgals8-/- mice displayed a faster disease onset and developed a more severe disease
during the chronic phase (Fig 1A and Table 1). Spinal cord histological analysis showed
enhanced inflammation (Fig 1B, i and ii) and demyelination (Fig 1B, ii and iv) in the affected
areas of Lgals8-/- mice. Such EAE exacerbation under Gal-8 deficiency suggests a protective
role of endogenous Gal-8 against CNS autoimmunity.
Gal-8 silencing leads to increased Th17 cells and Th1-like Tregs
To understand how the lack of Gal-8 predisposes the immune system to a more pronounced
CNS autoimmunity we compared lymphocyte subpopulations and the responses of spleen
cells to ex vivo anti-CD3/anti-CD28 activation and to re-stimulation with MOGp. Splenocytes
from Lgals8-/- and Lgals8+/+ littermates showed similar frequencies of B and T (CD4+ and
CD8+) lymphocytes, dendritic cells, and CD4+ T-cells subsets, including naive (CD4+CD25- or
Fig 1. Lack of endogenous Gal-8 expression exacerbates EAE. Lgals8+/+ (WT) and Lgals8-/- (Gal-8 KO) immunized with MOGp. (A) Clinical
scores monitored daily for 25 days show an exacerbated EAE in Gal-8 KO mice (***p<0.001; Mann Whitney; day by day clinical Score
comparisons; n = 20 WT; n = 22 Gal-8 KO). (B) Spinal cord histopathological analysis after 10 days of immunization show enhanced immune
cell infiltration and demyelination in Gal-8 KO mice, shown by H&E staining (I and II) and luxol fast blue staining (III and IV). Scale bar = 50 μm.
https://doi.org/10.1371/journal.pone.0177472.g001
Table 1. Clinical parameters of EAE progression.
Group of mice n Incidence
(%)
Day of Onset
(Mean ± SD)
Maximum Score
(Mean ± SD)
Time to Peak
(Mean ± SD)
Accumulative Score
(Mean ± SD)
Lgals8+/+ 20 85.2 13.5 ± 2.8 3.4 ± 0.7 15.9 ± 3.4 28.2 ± 11.9
Lgals8-/- 22 86.2 12.5 ± 2.6 3.6 ± 0.6 15.5 ± 3.2 40.7 ± 23.2*
*P < 0.05 comparing accumulative scores between WT and Gal-8 KO mice.
https://doi.org/10.1371/journal.pone.0177472.t001
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CD4+ CD62L+ CD44-), effector (CD4+ CD62L- CD44+) and memory (CD4+ CD62L+ CD44+)
T-cells (Fig 2A). However, Lgals8-/- splenocytes displayed higher polarization towards Th17
(CD4+ IL17+) after anti-CD3/anti-CD28 activation (Fig 2B).
We then compared the systemic expansion of Th1 and Th17 cells during EAE induction by
analyzing the splenocytes from Lgals8-/- and Lgals8+/+ mice after 10 days post-immunization
and ex vivo re-stimulation with MOGp. We did not detect meaningful differences in the fre-
quency of Th1 cells between Lgals8-/- and Lgals8+/+ mice (Fig 3). Th1 cells also remained unaf-
fected under ex vivo Gal-8 incubation (Fig 3). In contrast, splenocytes from Lgals8-/- mice
unstimulated or re-stimulated with MOGp ex vivo showed an increased frequency of Th17
cells compared with Lgals8+/+ littermates (Fig 3). Incubation with exogenous Gal-8 reduced
the frequency of Th17 cells in Lgals8-/- splenocytes to the levels of control mice (Fig 3), thus
contrasting with the lack of response seen in Lgals8+/+ splenocytes. Therefore, in the absence
of endogenous Gal-8 expression there is increased Th17 polarization, while in the presence of
endogenous Gal-8, the Th17 cells activated by MOGp immunization and likely involved in
EAE seem to be eliminated.
As Tregs have been shown to control Th17 and Th1-mediated tolerance and inflammatory
responses in MS and EAE [6], we analyzed total Tregs, as well as Tregs subpopulations that
suppress responses mediated by either Th1 (CXCR3+ CCR6-) [9, 10] or Th17 (CXCR3-
CCR6+) Tregs [11] lymphocytes. Unexpectedly, we found an increased frequency of total
Tregs (Foxp3+) in Lgals8-/- mice splenocytes compared to control mice (Fig 4). We also found
Fig 2. Gal-8 deficit favors selective Th17 cell differentiation upon polyclonal activation. Splenocytes isolated from Lgals8+/+ (WT) and Lgals8-/-
(KO) mice were analyzed by FACS: (A) Dendritic cells (CD11c+), B cells (CD19+), CD8+ T cells and different CD4+ T cells subsets, naïve (CD44-CD62L+),
effector (CD44+CD62L+), memory (CD44+CD62L-) and total cells analyzed in the subset of viable CD4+ CD25- T-cells show no differences between WT
and KO mice. Graphics of frequency +/-SD (n = 5). (B) T cell activation by 72 h incubation with anti-CD3 (anti-CD3) and anti-CD28 (anti-CD28) antibodies
show Th17 increased frequency in KO mice while Th1 and Th2 cells are similar in WT and KO mice. Graph shows frequency +/-SD (*p<0.05; ANOVA;
n = 4).
https://doi.org/10.1371/journal.pone.0177472.g002
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a highly increased frequency of CXCR3+ Tregs, whereas CCR6+ Tregs tended to decrease in
Lgals8-/- compared with control Lgals8+/+ mice (Fig 4). Therefore, the absence of Gal-8 leads to
an increase of Th17 polarization, as well as higher generation of CXCR3+ Tregs and lower fre-
quency of CCR6+ Tregs, which respectively would impact upon Th1 and Th17 functions [8].
Gal-8 ameliorates EAE and induces apoptosis of activated Th17 cells
The key role of endogenous Gal-8 in regulating the functions of effectors and Tregs during
EAE development prompted us to evaluate the impact of the exogenous Gal-8 treatment on
EAE induction and Th17 survival in wild-type C57BL/6 mice. Daily treatment with Gal-8
starting from disease induction significantly delayed the progression of EAE clinical symptoms
(Fig 5A and Table 2). To test the sensitivity of wild-type activated Th17 cells to Gal-8 treat-
ment, we differentiated Th17 cells in vitro and activated them with anti-CD3/anti-CD28.
Fig 4. Galectin-8 deficit increases the frequency of total Tregs and CXCR3+ Tregs. Splenocytes isolated
from Lgals8+/+ (WT) and Lgals8-/- (KO) mice were analyzed at steady state for total Tregs (Foxp3+), CXCR3+
and CCR6+ frequency in the Treg (Foxp3+ CD4+) population. Graphs of frequency +/-SEM show increased
total Tregs (Foxp3+) and CXCR3+Tregs in KO mice (*p<0.05; **p<0.01; p***<0.001; Student’s t-test; n = 4).
https://doi.org/10.1371/journal.pone.0177472.g004
Fig 3. Gal-8 deficit favors Th17 polarization during MOGp-induced EAE and ex-vivo re-stimulation.
Th17 and Th1 subpopulations in splenocytes from Lgals8-/- (KO) and Lgals8+/+ (WT) mice obtained after 10
days of EAE induction were analyzed either immediately or after 72 h of ex vivo MOGp re-stimulation, in the
absence or presence of Gal-8. Gal-8 KO mice show higher frequency of Th17 cells both at steady state and
after MOGp re-stimulation. Incubation with Gal-8 reduced Th17 cells only in Gal-8 KO. Graph shows
frequency +/-SD (*p<0.05; ANOVA; n = 4).
https://doi.org/10.1371/journal.pone.0177472.g003
Galectin-8 as an immunosuppressor blockable by autoantibodies in multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0177472 June 26, 2017 9 / 26
Annexin V/7-AAD staining showed that Gal-8 induced apoptosis of these Th17 activated cells
(Fig 5B). These results indicate that exogenous Gal-8 exert immune-suppressive action against
EAE induction involving apoptotic elimination of activated Th17 cells.
Fig 5. Gal-8 ameliorates EAE and induces Th17 cell death in vitro. (A) Gal-8 treatment ameliorates MOGp-induced EAE in C57BL/6 mice. The
mice were injected daily by intraperitoneal injection of either PBS (Control) or Gal-8 100 μg/ml. Gal-8-treated animals tend to start the disease later
and show lower EAE scores during the acute and chronic phases of the disease (*p<0.05; Control, n = 7; Gal-8 treated, n = 5). (B) Gal-8-induced cell
death in Th17 lymphocytes differentiated and activated in vitro. Naive (CD62L+ CD44-) CD4+ T cells were purified by cell sorting and differentiated to
a Th17 phenotype. The differentiated Th17 cells were isolated with a commercial kit based on the cell surface expression of IL-17 and activated with
anti-CD3/anti-CD28 in the presence or absence of Gal-8 (20 μg/ml) for 72 h. Cell death was determined by cell staining with Annexin V and 7-AAD
and analyzed by FACS. Representative dot plots show the frequency of Th17 cells before and after purification (upper panels), the selected gate in
the forward scatter versus side scatter analysis (middle panels) and the associated contour-plots show the Annexin V versus 7-AAD analysis (lower
panels). Numbers in quadrants indicate the percentage of cells in the respective quadrant.
https://doi.org/10.1371/journal.pone.0177472.g005
Table 2. Clinical parameters of EAE disease progression (day 0–20).
Group of mice n Day of Onset
(Mean ± SD)
Maximum Score
(Mean ± SD)
Time to Peak
(Mean ± SD)
Accumulative Score
(Mean ± SD)
Vehicle 7 12.7 ± 1.7 4.1 ± 0.8 16.4 ± 2.4 20.8 ± 8.0
Gal-8 treatment 5 13.6 ± 0.9 2.8 ± 1.6 17.8 ± 1.4 10.1 ± 7.0*
*P < 0.05 comparing accumulative scores of mice injected with either vehicle or Gal-8.
https://doi.org/10.1371/journal.pone.0177472.t002
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Gal-8 expression in the brain
Although peripheral events tailoring the immune system contribute to MS and EAE pathology,
most of the autoimmune pathogenic condition unfolds inside the CNS [3]. In our knock-in
Lgals8 mice the β-galactosidase (β-gal) cassette reporter gene replaces the entire Gal-8 gene
with LacZ, thus offering the possibility to assess the activity of the corresponding promoter by
β-gal histochemistry [40–42]. This analysis revealed Gal-8 expression in several brain regions
(Fig 6A; S1 Table). Interestingly, the choroid plexus, which generates CSF [47], displayed high
expression levels, suggesting that Gal-8 might be secreted into the CSF. To test this possibility
we analyzed CSF from patients studied for other pathologies, mainly cephalea, and included
one patient with meningitis. We detected Gal-8 in all CSF samples with variable intensity. The
highest levels corresponded to a patient studied for cephalea (Fig 6B). These results suggest
that Gal-8 produced by the choroid-plexus is a component of the CSF.
Patients with MS generate function-blocking antibodies against Gal-8
The results showing an immunosuppressive and protective role of Gal-8 against EAE
prompted us to assess whether patients with MS generate blocking-function anti-Gal-8 anti-
bodies, as previously reported in LES and AR patients [39, 46]. Using recombinant human
Gal-8 [37] and immunoblot analysis [39] we found clear evidence of anti-Gal-8 autoantibodies
in a cohort of RRMS patients (Fig 7). We also found evidence of the presence of anti-Gal-8
antibodies in CSF, either coincident or independent of serum reactivity (Fig 7).
To evaluate whether MS patients generate function-blocking anti-Gal-8 autoantibodies we
performed two assays. The established assay of cell adhesion to Gal-8-coated coverslips, which
assesses glycan-mediated interaction of Gal-8 with integrins [37, 38], showed that anti-Gal-8
(+) serum from RRMS patients decreases the adhesion of peripheral blood mononuclear cells
(PBMC) (Fig 8A). In addition, we tested the potential of MS-generated anti-Gal-8 antibodies
to counteract the apoptotic effect of Gal-8 on activated Th17 cells showed above in Fig 5B.
Affinity purified anti-Gal-8 antibodies from a pooled anti-Gal-8(+) sera effectively decreased
Fig 6. Gal-8 expression in mouse brain and presence in human CSF. (A) Histochemistry of β-gal staining reveals Gal-8 expression in several
regions of the mouse brain (S1 Table). Brain slices depict high Gal-8 expression levels in the choroid plexus (CP) of the lateral ventricle (LV) and the
dorsal 3rd ventricle (D3V), as well as in the ventrolateral thalamic nucleus. (B) Immunoblot with rabbit anti-Gal-8 antibody show Gal-8 reactivity in the
CSF of individuals without MS. Samples C3-11 correspond to non-inflammatory CSF from individuals studied for diplopia (C3), vertiginous syndrome
(C7), cephalea (C8 and C11) and febrile syndrome (C9), whereas C6 is an inflammatory CSF from a patient with meningitis. All samples show anti-Gal-8
reactivity, though with variable intensity. *Bands of unknown origin might include Gal-8 dimers or complexes with other proteins, not separable under
SDS-PAGE conditions.
https://doi.org/10.1371/journal.pone.0177472.g006
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the apoptosis rate of activated Th17 cells incubated with Gal-8 (Fig 8B). These results indicate
that patients with RRMS generate function-blocking anti-Gal-8 antibodies, which have the
potential to neutralize the immunosuppressive role of Gal-8.
Circulating anti-Gal-8 antibodies are associated with worse prognosis in
patients with RRMS
As the presence of anti-Gal-8 neutralizing antibodies might mimic the condition of Gal-8
silencing that exacerbates EAE, we next explored the impact of these antibodies on the clinical
course of MS. We studied 58 patients, 36 with recent diagnosis of RRMS and 22 with a pro-
gressive disease (8 with SPMS and 14 with PPMS). The results show that 33% (19/58) of these
patients have anti-Gal-8 antibodies. Interestingly, 90% of the patients bearing Gal-8(+) sera
corresponded to the RRMS phenotype. Within the group of RRMS patients, 17 out of 36 had
Gal-8 autoantibodies (47%). In contrast, only 9% of patients with progressive forms (2/22)
had anti-Gal-8 autoantibodies (p = 0.006, Yates chi-square corrected p value = 0.006. Odds
ratio = 8.947; 95% confidence interval = 1.817–44.054) comparing RRMS versus progressive
MS) (Table 3). We previously reported a similar Gal-8 antibody frequency of about 10% in
healthy individuals [39]. Therefore, even though anti-Gal-8 autoantibodies are not specific for
MS [39], their presence associated with RRMS and not with progressive MS phenotypes.
We next analyzed whether anti-Gal-8 antibodies associate with worse prognosis in RRMS
patients. Before starting the DMD treatment, RRMS patients with or without Gal-8 autoanti-
bodies showed no differences in age, gender, age at onset, disease duration, EDSS, and pres-
ence of baseline gadolinium-enhanced T1 lesions (S2 Table). However, clear differences
appeared during an average of 12 months of follow-up. EDSS worsening occurred with higher
frequency in anti-Gal-8(+) patients, independently of treatment and relapse number (Fig 9A;
Fig 7. Detection of Gal-8 autoantibodies in sera and CSF from MS patients. Immunoblot of sera and CSF from different MS
patients (Pn) against Gal-8 indicating its (-) or (+) anti-Gal-8 reactivity compared with a negative control (C) from a healthy individual. In
some patients (e.g. P2 and P10) anti-Gal-8 reactivity was detected in both sera and CSF, while in others (e.g. P3) was only detected in
CSF. P14 is shown only in CSF but is also positive in serum (analyzed in other immunoblot), while P15 and P17 are negative both in
CSF and serum (not shown). In most patients (e.g. P4-6) only sera could be analyzed. P9 was only analyzed in CSF.
https://doi.org/10.1371/journal.pone.0177472.g007
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Fig 8. Function-blocking activity of anti-Gal-8 autoantibodies. (A) Anti-Gal-8(+) sera block the adhesion of PBMC to Gal-
8-coated coverslips. Graph shows number of adhered cells (Average ± SE of three anti-Gal-8(-) and three anti-Gal-8(+) sera
tested in triplicate) (***p<0.001; Student’s t-test). (B) Anti-Gal-8 autoantibodies inhibit Gal-8-induced apoptosis of Th17 cells. In
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Table 4; mean EDSS 1.5 vs 0, p = 0.02). Five out of 17 patients with anti-Gal-8(+) sera had clin-
ically relevant EDSS worsening, while none of the anti-Gal-8(-) patients worsened during this
follow-up period (Fig 9B; p = 0.016).
Considering our previous results in mice, the association of anti-Gal-8 antibodies with
severity in RRMS patients might be due to an interference with the immunosuppressive role of
Gal-8. Within the RRMS group of patients these antibodies constitute a potential early prog-
nostic marker.
Discussion
Our results demonstrate a crucial role of Gal-8 and its function-blocking antibodies in the
pathogenesis of MS. We first show that Gal-8 exerts an immunosuppressive protective influ-
ence against EAE, as revealed by both the enhanced disease developed in Gal-8 KO mice
and the ameliorating effect of Gal-8 treatment. The mechanism likely involves a modulating
action on the balance of Th1 and Th17 cell polarization and differentiation of their respective
CXCR3+ and CCR6+ Tregs. We then show that patients with MS generate function-neutraliz-
ing Gal-8 antibodies that can counteract the immunosuppressive Gal-8 function. Our clinical
analysis disclosed an association of circulating anti-Gal-8 antibodies with worse evolution
in newly diagnosed and still untreated RRMS patients, showing EDSS worsening within the
first year of follow up. Thus, anti-Gal-8 antibodies emerge as a potential early prognostic
biomarker.
We show that Gal-8 KO mice at steady state display increased CXCR3+ Tregs and decreased
CCR6+ Tregs frequencies, developing exacerbated EAE accompanied by an increased pola-
rization toward Th17 cells after MOG immunization. In vitro, Gal-8 reduces the Th17 cell
response to re-stimulation with MOG only in splenocytes from MOG-immunized Gal-8 KO
but not from wild-type mice. Th1 cells are not affected. This suggests that Gal-8 eliminates
activated Th17 but not Th1 cells during in vivo immunization. In congruency, we found that
Gal-8 induces apoptosis of anti-CD3/anti-CD28 activated Th17 cells in vitro. The relative con-
tribution of Th1 versus Th17 cells in MS pathogenesis remains contentious [3]. The Th17/Th1
ratio likely influences the inflammatory regions in the CNS [48]. Dysregulation of Th17 cells
seems to be a main driver of inflammation [49–51], while Th1 lymphocytes producing IFN-γ
vitro differentiated Th17 cells from IL-17A-GFP reporter mice were purified based on IL-17A expression (GFP+) and incubated
with Gal-8 (20 μg/ml) in the presence of lactose, sucrose or anti-Gal-8 antibodies affinity purified from pooled serum of MS
patients. The extent of apoptosis was quantified as the frequency of Annexin V+ 7AAD+ cells of the sample relative to the
frequency of Annexin V+ 7AAD+ cells of the untreated control. Representative contour plots are shown in upper panels.
Quantification of a representative experiment is shown in the lower panel. Values represent mean + SEM of triplicates. Data from
a representative from four independent experiments is shown. **, p<0.01; ***, p < .001 by one-way ANOVA followed by
Tukey’s post-hoc test.
https://doi.org/10.1371/journal.pone.0177472.g008
Table 3. Frequency of anti-Gal-8 autoantibodies in 58 patients with multiple sclerosis according to relapsing-remitting (RRMS) or progressive
forms.
Multiple Sclerosis
Autoantibodies Relapsing-Remitting Progressive
n = 36 n = 22
anti-Gal-8 (+) 17 (47%) 2 (10%)
anti-Gal-8 (-) 19 (53%) 20 (90%)
Patients with RRMS had higher frequency of anti-Gal-8 antibodies than progressive forms. Yates chi-square corrected p value = 0.006. Odds ratio = 8.947
(95% confidence interval = 1.817–44.054).
https://doi.org/10.1371/journal.pone.0177472.t003
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can play either inflammatory or protective roles [52–54]. Although there is evidence indicating
that Th17 cells predominate over Th1 cells in EAE [1, 49, 50, 55], other studies suggest that
both Th1 and Th17 cells can drive autoimmune-mediated CNS pathology [48, 56]. Our results
of Th17 polarization together with the alterations in CXCR3+ and CCR6+ Tregs, configuring
Fig 9. Anti-Gal-8 autoantibodies correlate with worse disability scores in RRMS patients. (A) RRMS
patients with and without autoantibodies were followed during an average of 12 months. Patients (n = 17)
with anti-Gal-8(+) sera have worse EDSS at the end of follow-up than patients (n = 19) without anti-Gal-8
autoantibodies (mean EDSS 1.5 vs 0, *p = 0.002, nonparametric Mann-Whitney U test), independent of the
treatment received or number of relapses during this period. (B) At the end of follow-up, 5/17 patients with
anti-Gal-8 autoantibodies developed confirmed EDSS worsening vs 0/19 of patients without anti-Gal-8
autoantibodies (*p = 0.016 by Fisher test).
https://doi.org/10.1371/journal.pone.0177472.g009
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an immunologic context prone to develop an exacerbated EAE, support the notion that both
Th17 and Th1 functions are compromised in the pathogenesis of this disease.
An immunosuppressive role for Gal-8 has been originally suggested by its apoptotic effect
on Jurkat T cells and CD3/CD28-activated human peripheral T cells [29]. Such an apoptotic
effect involved a little known signaling pathway, in which Gal-8 increases phosphatidic acid
leading to ERK activation and phosphodiesterase-4-mediated down regulation of protein
kinase A [29]. More recently, Gal-8 was shown to kill in vitro differentiated Th17 cells, as we
corroborated here in a different setting, and to promote the differentiation of Tregs with ame-
liorating effects on EAU [30]. In a mouse model of autoimmune uveitis involving exacerbated
Th1 and Th17 activities and Treg dysfunction, Sampson et al. [30] showed that Gal-8 treat-
ment increased the differentiation of Tregs at sites of ongoing inflammation, such as draining
lymph nodes and retina, but not systemically, as the spleen CD4+ T cell subpopulations
remained unchanged. These Gal-8-polarized Tregs expressed CTL-4 and IL-10 markers of
immune suppression activity and most of them lacked neurophilin expression, suggesting a
peripheral rather than thymic origin [30]. Gal-8 also promoted the differentiation of Tregs
with high immunosuppressive properties from splenic CD4+ T-cells in vitro, modulating the
known roles of IL-2 and TGF-β receptors in this process [31]. These acute effects most likely
contribute to ameliorate the severity of autoimmune uveitis in mice treated with Gal-8 [30], as
well as EAE in our present experiments.
However, our results reveal a more complex role of Gal-8 on Treg homeostasis than previ-
ously appreciated from studies showing Gal-8-promoted Treg differentiation [30, 31]. At
steady state, Gal-8 KO mice have lower frequency of CCR6+ Tregs, which are suppressors of
Th17-mediated inflammation [8]. This condition, together with increased Th17 cells, probably
provides an important background for the exacerbated EAE developed by these animals.
Endogenous Gal-8 could be required for appropriate differentiation of these particular Tregs.
However, the chronic deficit of Gal-8 function in KO mice clearly configures a more complex
condition. Instead of resulting in a lower Treg polarization, Gal-8 KO mice have increased
total Tregs, mostly composed of CXCR3+Tregs, which should compromise Th1-mediated
functions [8]. Such Treg imbalance might originate at the thymus where Gal-8 has been
shown to be expressed and can induce thymocyte apoptosis [57]. Indeed, a deficit in the
Table 4. Different EDSS outcome in RRMS patients according to the presence of anti-Gal-8
autoantibodies.
Relapsing-Remitting Multiple Sclerosis Anti-Gal-8
(+)
n = 17
Anti-Gal-8
(-)
n = 19
Mann-
Whitney
U test
p Value
Disease Duration (years) since first symptoms to baseline;
Median (range)
2.0 (1–16) 3.0 (1–9) 0.54
Follow-up (years) since baseline to last assessment Median
(range)
1.1 (0.1–
1.8)
1.8 (0.1–
2.4)
0.62
Annualized relapse rate Median (range) 0.8 (0.1–
1.7)
0.6 (0.2–
1.9)
0.24
Baseline EDSS (Scale 0–10); Median (range) 0.0 (0.0–
1.5)
0.0 (0.0–
2.0)
0.93
Final EDSS (Scale 0–10); Median (range) 1.5 (0.0–
5.0)
0 (0.0–1.5) 0.02
RRMS: Relapsing-remitting multiple sclerosis; SD: Standard deviation. Mann-Whitney U test. Evolution is
independent of relapse number and associates with the presence of anti-Gal-8 autoantibodies. Patients with
anti-Gal-8 autoantibodies had worse EDSS.
https://doi.org/10.1371/journal.pone.0177472.t004
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reported Gal-8-modulation of IL-2 and TGF-β receptors [31], crucial for Treg differentiation
and many other immune processes [6, 58], might underlie this alteration. The exacerbated
EAE of Gal-8 KO mice and the expression of CXCR3 in the FoxP3+ T cell population suggest a
Treg polarization distinct from the immunosuppressive-competent Tregs differentiated under
a Gal-8 environment [30, 31]. In the absence of Gal-8, Treg polarization might mimic the
immunosuppressive-defective and proinflammatory CXCR3+ Tregs found enriched in RRMS
patients [59]. Interestingly, Th1-suppressive CXCR3+ Tregs play protective roles under tran-
sient inflammatory stimuli [9, 10, 60], but are reprogrammed to effector Th1 cells producing
IFN-γ with inflammatory activity during sustained or chronic inflammation [8, 60]. IFN-γ, the
hallmark Th1 cytokine, can promote both protective and pathogenic roles in EAE and MS
[52–54]. RRMS patients display a higher frequency of Tregs with an IFN-γ-expressing Th1-like
phenotype that has reduced suppressive activity [59]. Furthermore, IFN-β, a first-line DMD
therapy for RRMS returns the frequency of Th1-like CXCR3+ Tregs to that of healthy controls
and increases the frequency of Th17 suppressive Tregs [59]. Therefore, the exacerbated EAE
developed by Gal-8 KO mice, similarly to RRMS, likely involves dysregulation of Th1-and
Th17-suppressive Tregs. Gal-8 might be a master regulator of Treg subpopulations that sup-
press Th1- and Th17-mediated functions and consequently might modulate the pathogenic
effector functions of Th1 and Th17 cells in MS.
The high expression levels of Gal-8 found in the choroid plexus of mouse brain and the
presence of Gal-8 in human CSF suggest a direct role of Gal-8 in the CNS immune-surveil-
lance circuit. The immune-surveillance circuit includes subarachnoid regions bathed in CSF
and the deep cervical lymph nodes where dura lymphatic vessels drain CSF from the brain [3,
61, 62]. Therefore, Gal-8 present in the CSF might modulate autoimmune inflammatory
events at all these locations. In addition, the choroid plexus generates and regulates CSF and
constitutes the main gate for T cells to cross the blood-CSF barrier during immune surveil-
lance and the initial stages of EAE [3]. Th17 cells express the receptor CCR6 for the chemokine
CCL20, which is constitutively expressed in the choroid plexus and is fundamental for EAE
development [63]. Whether Gal-8 interacts with CCR6 remains unknown. However, CNS
homing of MS- and EAE-pathogenic Th1 and Th17 cells also depends on α4β1 integrin and
LFA-1 integrins, respectively [48, 64–66]. Gal-8 binds poorly to α4β1 integrin [37], but effec-
tively binds to LFA-1 and inhibits its interaction with ICAM [38]. It is thus possible that Gal-8
produced in the choroid plexus restricts CNS homing mainly of Th17 cells, the first T cell sub-
set that migrates into the CNS during EAE [3].
In addition, our results suggest that an impaired Gal-8 immunosuppressive role in MS,
mimicking the autoimmune CNS enhanced condition of Gal-8 KO mice, might occur within
an autoimmune context that generates anti-Gal-8 neutralizing antibodies similar to those
described in SLE [29, 37–39]. Our early studies showed that Gal-8-induced apoptosis of Jurkat
cells can be counteracted by anti-Gal-8 antibodies from lupus patients, thus suggesting for the
first time a role of these antibodies in autoimmunity [29]. Here we detected anti-Gal-8 anti-
bodies in both the serum and CSF of MS patients. The circulating anti-Gal-8 antibodies
obtained from MS patients blocked cell adhesion to Gal-8 and also the apoptotic effect of Gal-
8 upon activated Th17 cells. Our clinical analysis suggests a pathogenic role of these antibodies.
Anti-Gal-8 antibodies detected in serum associated with RRMS and not with the progressive
forms of the disease. This might reflect differences in the autoimmune status between the dif-
ferent stages and phenotypes of the disease [1, 3] and could help to precisely diagnose uncer-
tain cases. More importantly, these antibodies predict RRMS prognosis. The clinical course of
RRMS is heterogeneous, varying from few relapses and low physical burden to rapid accumu-
lation of disability [2]. As shown by clinically relevant EDSS worsening, RRMS patients bear-
ing circulating Gal-8 antibodies at the moment of diagnosis have higher probability of
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disability progression within an evolution period of 12 months. Despite the small sample size
and low EDSS scores, our data reached statistical significance associating clinical disability
progression with anti-Gal-8 antibodies. The experimental evidence of an immunesuppressive
role of Gal-8 in EAE provides robust mechanistic rational to these clinical findings. Therefore,
MS patients can generate function-blocking anti-Gal-8 antibodies with pathogenic potential,
as they can neutralize the immunosuppressive role of endogenous Gal-8 that would normally
ameliorate CNS inflammation. Biomarkers that predict higher probability of developing dis-
ability at the moment of MS diagnosis, thus helping to optimize a personalized therapy, have
long been pursued and are still lacking [67, 68]. Our results open a new possibility pointing to
Gal-8 antibodies as suitable serum biomarkers for worse prognosis in recently diagnosed
RRMS patients. Indeed, such an important possibility would require further validation in a
larger cohort of patients.
A pathogenic role of antibodies in MS pathogenesis has long been debated [14]. Against
such a role are the rapid responses elicited by B-cell depleting therapy almost without affecting
antibody levels [3, 14]. B-cell functions such as antigen presentation and immune regulation
independent of antibody production have been involved in MS evolution [69]. On the other
hand, intrathecal production of oligoclonal bands, clonal expansion of B cells coinciding in
CSF and lesions, detection of antibodies and complement deposition in CNS lesions, the pres-
ence of follicle-like aggregates in the meninges and the beneficial effects of plasmapheresis in
some patients are all circumstantial evidence supporting a pathogenic role of antibodies [3,
14]. The identification of clinically relevant antigens is still a major problem [14]. MS patients
generate autoantibodies against neurons, oligodendrocytes, astrocytes and immune cell-spe-
cific antigens, encompassing a wide range of cell surface and intracellular molecules, including
proteins, lipids, glycans, gangliosides and DNA [70]. Studies on relevant targets have been
focused on myelin and axonal elements that might mediate demyelination and neurodegen-
eration [14, 71]. The most studied antibodies against MOG [72, 73], two components of the
node of Ranvier, neurofascin [74] and contactin [75] and the potassium channel KIR4.1,
expressed in glial cells [76, 77], have experimentally demonstrated pathogenic potential but so
far do not correlate with clinical evolution [14]. Oligoclonal IgM bands against myelin lipids
present in CSF predict aggressive evolution of RRMS [78–81], but their extensive use as bio-
markers seems limited by methodological difficulties [71, 82]. Our results point instead to a
circulating antibody compromising the function of an immune suppressor factor, such as Gal-
8, involved in the Th17, Th1 and Treg cell homeostasis. Neutralizing Gal-8 antibodies might
underlie risk conditions for worse RRMS evolution counteracting Gal-8-mediated immune-
modulating functions.
Several endogenous galectins probably contribute to the attenuation of autoimmune-
inflammation in the CNS through both redundant and complementary pathways. Gal-1- and
Gal-9-deficient mice develop more severe EAE due to selective expansion of antigen-specific
Th1 and Th17 cells and to increased immunogenicity of dendritic cells [20, 83]. In contrast,
Gal-3 deficiency reduces the severity of EAE [26]. The fact that mice lacking Gal-1, Gal-9 or
Gal-8 all develop more severe EAE suggests that the remaining galectins cannot compensate
for the absence of any of the others. Fine variations in their CRD preference for galactose-con-
taining oligosaccharides can underlie complementary roles of these lectins [19–22]. The N-
terminal CRD of Gal-8 has a unique high affinity for α2,3-sialylated glycans [27, 28]. There-
fore, Gal-1, Gal-9 and Gal-8 can sustain immune-suppressive conditions sensitive to disrup-
tion by the absence or decreased function of any of them.
Galectins also offer new therapeutic opportunities. Gal-1 and Gal-9 enhance the frequency
and immunosuppressive capacity of Treg cells [84, 85] and reduce EAE [20, 86]. Gal-1 also
attenuates EAE severity decreasing the activation of microglia [25]. As we show here, Gal-8
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treatment ameliorates EAE and might be especially indicated to counteract the severity in
RRMS patients bearing Gal-8 function-blocking antibodies. It would be interesting to assess
whether RRMS patients also generate neutralizing antibodies against Gal-1 and Gal-9 associ-
ated with worse prognosis.
In conclusion, our results point to Gal-8 as an endogenous immunosuppressor that limits
the autoimmune attack on the CNS, which can be blocked by antibodies leading to worse
prognosis. Our clinical results together with a plausible pathogenic mechanism suggest that
circulating anti-Gal-8 antibodies might be an early prognostic maker in RRMS and prompt to
consider a therapeutic use of this lectin in patients bearing anti-Gal-8 antibodies.
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the last 4 h of culture cell were stimulated incubating with 50 ng/ml PMA, 500 ng/ml ionomy-
cin, and 10 μg/ml brefeldin A. Tables show frequencies for Th1, Th2 and Th17 in Lgals8+/+
(WT) and Lgals8-/- (KO) mice in untreated condition (UN) or under polyclonal activation
(aCD3/28). Fig 2B: Splenocytes isolated from Lgals8+/+ (WT) and Lgals8-/- (KO) mice ana-
lyzed by FACS: (A) Dendritic cells (CD11c+), B cells (CD19+), CD8+ T cells and different
CD4+ T cells subsets, naïve (CD44-CD62L+), effector (CD44+CD62L+), memory (CD44+-
CD62L-) and total cells analyzed in the subset of viable CD4+ CD25- T cells. Results from 4–8
independent experiments show that Gal-8 deficit favors selective Th17 cell differentiation
upon polyclonal activation.
(PDF)
S3 File. Raw data of Fig 3: Frequencies of Th1 and Th17 subpopulations in splenocytes
from 10 day-induced EAE Lgals8-/- (KO) and Lgals8+/+ (WT) mice re-stimulated for 72 h
with MOGp in the absence (UN) or presence of Gal-8.
(PDF)
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S4 File. Raw data of Fig 4. Splenocytes isolated from Lgals8+/+ (WT) and Lgals8-/- (KO) mice
analyzed at steady state for total Tregs (Foxp3+), CXCR3+ and CCR6+ frequency in the Treg
(Foxp3+ CD4+) population. Upper Table: Total Tregs obtained from five WT and five
Gal8-KO mice (upper table). Middle Table: CXCR3+CCR6-. Bottom Table: CXCR3-CCR6+.
Analysis from three WT and three Gal8-KO mice. Data show that galectin-8 deficit increases
the frequency of total Tregs and CXCR3+ Tregs.
(PDF)
S5 File. Raw data of Fig 5 and Table 2: Daily clinical score of EAE Gal-8-treated versus
vehicle–treated WT mice. EAE was induced in wild-type C57BL/6J mice and simultaneously
treated (i.p.) with either 100 μg recombinant Gal-8 or PBS (control group) during 20 consecu-
tive days. EAE symptoms monitored daily using the following scale: 0, no clinical signs; 1, loss
of tail tone; 2, flaccid tail; 3, incomplete paralysis of one or two hind legs; 4, complete hind
limb paralysis; 5, moribund 6, death.
(PDF)
S6 File. Raw data of Fig 8A. Number of adherent cells counted in six randomly selected fields
after incubation with anti-Gal-8 autoantibodies from three positive (MS10, MS14 and MS20)
and three negative patients (MS 21, MS 18 and MS27). Anti-Gal-8 autoantibodies inhibit cell
adhesion.
(PDF)
S7 File. Raw data of Fig 8B. In vitro differentiated Th17 cells from IL-17A-GFP reporter mice
were purified based on IL-17A expression (GFP+) and incubated with Gal-8 (20 μg/ml) in the
presence of lactose, sucrose or anti-Gal-8 antibodies affinity purified from pooled serum of
MS patients. Numbers are the frequency of Annexin V+ 7AAD+ cells of the treated sample rel-
ative to the frequency of Annexin V+ 7AAD+ cells of untreated control, representing apoptosis,
from three independent experiments. Anti-Gal-8 autoantibodies inhibit Gal-8-induced apo-
ptosis of Th17 cells.
(PDF)
S8 File. Raw data of Patients. Clinical characteristic of 17 RRMS patients anti-Gal-8(+) and
19 RRMS patients anti-Gal-8(-): N (number of patient); Gender (1 is man and 0 is woman);
Age (is age at Anti-Gal-8 assay in years); Age at onset MS (age at first symptoms in years);
Diagnostic delay (time between age of onset and age of MS diagnosis); Disease duration (years
between onset of MS and age at sample assay); Basal EDSS (EDSS at moment of Anti-Gal
assay); Brain MRI Gd+ (number of Gadolinium enhancement T1 lesions at brain at moment
of Anti-Gal assay); Spinal MRI Gd+ (number of Gadolinium enhancement T1 lesions at spinal
cord at moment of Anti-Gal assay); DMD treatment (DMD treatment after Anti-Gal assay);
Final EDSS (EDSS at follow-up); ARR (annual relapses rate in follow-up); Follow-up (years of
follow-up after anti-Gal-8 assay).
(PDF)
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